Weight Loss and Wasting Remain Common Complications in Individuals Infected with Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy | Zendy

C. A. Wanke | Zendy; M. Silva | Zendy; T. A. Knox | Zendy; Janet Forrester | Zendy; Donna Speigelman | Zendy; S. L. Gorbach | Zendy

Open Access

Weight Loss and Wasting Remain Common Complications in Individuals Infected with Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy

Author(s) -

C. A. Wanke,

M. Silva,

T. A. Knox,

Janet Forrester,

Donna Speigelman,

S. L. Gorbach

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/314027

Subject(s) - wasting , medicine , cohort , cohort study , weight loss , prospective cohort study , human immunodeficiency virus (hiv) , antiretroviral therapy , wasting syndrome , sida , pediatrics , viral disease , immunology , viral load , obesity

It has been postulated that the use of highly active antiretroviral therapy (HAART) would reduce the occurrence of human immunodeficiency virus (HIV)-associated weight loss and wasting. To test this assumption, we evaluated, by means of longitudinal analysis, a prospective cohort of 469 HIV-infected individuals enrolled in a study of the impact of HIV on nutrition. Overall, 156 individuals in the cohort (33.5%) met at least 1 of these definitions of wasting. Furthermore, 58% of the cohort (289 patients) lost >1.5 kg of weight in a 6-month period between any 2 study visits. More than 50% of the cohort was receiving HAART at the time that they met 1 of the definitions of wasting; with regard to the occurrence of wasting; no differences were related to therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research